The Newsroom

Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.

Press Release

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics presents promising data on RTNova™, a novel systemic virotherapy technology designed to target metastatic lung cancer and other advanced cancers by overcoming immune clearance and enhancing therapeutic targeting

Discover More

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces Appointment of Jim Schoeneck, Accomplished Biotech Executive, to Board of Directors

July 1, 2020

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at AACR 2020 Virtual Annual Meeting II

June 22, 2020

Publication

event

SuperNova (SNV)

NeuroNova

Supernova

RTNova

Enhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms.

Journal of Clinical Oncology

May 25, 2020

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

RTNova

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

The Journal of Translational Medicine

May 18, 2020

Blog

event

NeuroNova

Supernova

RTNova

Calidi’s Contribution To The Treatment Of COVID-19

In A Short Time, The Novel Coronavirus Disease (COVID-19) Has Destructively Impacted Both The People Of The World And The Global Economy On A Historic Scale. As Of April 27th 2020, The World Health Organization (WHO) Reports Over 3,002,303 Confirmed Cases Globally, With The Worldwide Death Toll Rising Above 208,131.

April 27, 2020

Press Release

event

NeuroNova

Supernova

RTNova

Stem Cells for COVID-19 | PSC Teams Up with Calidi Biotherapeutics

April 22, 2020

Press Release

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

November 18, 2024

Discover More

Press Release

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

November 15, 2024

Discover More

Press Release

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

November 14, 2024

Discover More

Press Release

Calidi Biotherapeutics Announces Proposed Public Offering

November 13, 2024

Discover More

Press Release

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the third quarter ended September 30, 2024

November 12, 2024

Discover More

Press Release

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

Calidi Biotherapeutics, Inc. will present data on RTNova, its systemic antitumor virotherapy platform, at several upcoming scientific conferences, including the International Oncolytic Virotherapy Conference in Rotterdam and Immuno US 2024 in San Diego. RTNova offers a novel approach to treating previously untreatable metastatic cancers by targeting multiple tumor sites and altering the tumor immune microenvironment. Dr. Antonio F. Santidrian and Dr. Duong H. Nguyen will lead these presentations, which have been crucial in advancing this innovative therapy.

October 24, 2024

Discover More

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

The Journal of Translational Medicine

May 18, 2020

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

ASCO-SITC Clinical Immuno-Oncology Symposium February 6-8, 2020 Orlando, Florida.

Abstract 21: A cell-based platform to potentiate oncolytic virus therapies

February 6, 2020

Publication

event

SuperNova (SNV)

NeuroNova

Supernova

A cell-based platform to potentiate oncolytic virus: Potential approach for cancer therapies.

Journal of Clinical Oncology

February 4, 2020

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

The Journal of Translational Medicine

August 19, 2019

Publication

event

SuperNova (SNV)

NeuroNova

Supernova

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

The Journal of Translational Medicine

August 19, 2019

Publication

event

SuperNova (SNV)

NeuroNova

Supernova

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

The Journal of Translational Medicine

March 27, 2019

Media

Good Morning San Diego, Calidi Bio Treatments Discussed

April 13, 2019

Discover More

Media

KUSI San Diego News - Calidi Bio CEO, Allan Camaisa Interviewed

April 12, 2019

Discover More

In The News

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Calidi Biotherapeutics Inc (NYSE: CLDI) is making waves in the biotech industry with its innovative approach to cancer treatment. The company utilizes allogeneic stem cells to deliver oncolytic viruses directly to tumors, offering new hope for patients.

October 9, 2023

Discover More

In The News

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Baird initiates coverage on Calidi Biotherapeutics Inc CLDI, which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment. Just a month back, Calidi Biotherapeutics became the latest biotech to take the special purpose acquisition company route to the public market

October 9, 2023

Discover More

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.

Learn more

The Newsroom

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics Announces Appointment of Jim Schoeneck, Accomplished Biotech Executive, to Board of Directors

Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at AACR 2020 Virtual Annual Meeting II

Enhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms.

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

Calidi’s Contribution To The Treatment Of COVID-19

Stem Cells for COVID-19 | PSC Teams Up with Calidi Biotherapeutics

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

Calidi Biotherapeutics Announces Proposed Public Offering

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

ASCO-SITC Clinical Immuno-Oncology Symposium February 6-8, 2020 Orlando, Florida.

A cell-based platform to potentiate oncolytic virus: Potential approach for cancer therapies.

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

Good Morning San Diego, Calidi Bio Treatments Discussed

KUSI San Diego News - Calidi Bio CEO, Allan Camaisa Interviewed

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

All Courses

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.